Literature DB >> 11504957

Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy.

M Birk1, V Svedhem, A Sönnerborg.   

Abstract

OBJECTIVE: To study the kinetics of HIV-1 RNA and drug-induced mutations after cessation of antiretroviral therapy (ART). DESIGN AND METHODS: Successive plasma samples from 26 patients were tested for HIV-1 RNA by PCR and for mutations associated with drug resistance by sequencing of the pol gene.
RESULTS: After cessation of ART the phase of undetectable virus (< 50 copies/ml), ranging from 6 to more than 29 days, was followed by a rapid viral increase, which slowed down before a plateau corresponding to pre-treatment levels or higher was reached in most cases (14/19 patients). In one patient virus was still undetectable at 4 weeks. Also, a significantly larger number of primary protease inhibitor (PI)-associated mutations reverted to wild-type, as compared with secondary PI-, and primary reverse transcriptase inhibitor (RTI)-associated mutations. During the rapid viral increase no mutations disappeared, which instead happened during the slower viral increase preceding the viral plateau level.
CONCLUSION: After discontinuation of ART large individual variations were found for the time period until HIV-1 became detectable in plasma, possibly due to differences in the HIV-1 specific immunity. The more rapid loss of primary PI mutations suggests that they might cause a more impaired viral fitness than primary RTI mutations. However, the persistence of drug mutations during the initial viral load increase indicates that mutated strains may still replicate efficiently.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11504957     DOI: 10.1097/00002030-200107270-00005

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  5 in total

1.  Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.

Authors:  Marc Wirden; Constance Delaugerre; Anne Genevieve Marcelin; Nadine Ktorza; Hocine Ait Mohand; Stephanie Dominguez; Luminita Schneider; Jade Ghosn; Michele Pauchard; Dominique Costagliola; Christine Katlama; Vincent Calvez
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

2.  Differences in the frequency of resistance to antiretroviral drug classes among human immunodeficiency virus type 1 clinical isolates.

Authors:  Rafael E Campo; Paola N Lichtenberger; Isabella Rosa; German Suarez; Fernando A Rivera; Allan E Rodriguez; Dushyantha T Jayaweera; Natalie A Wahlay; Michael A Kolber
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

Review 3.  Minority variants of drug-resistant HIV.

Authors:  Sara Gianella; Douglas D Richman
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

4.  Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma.

Authors:  Giovanina M Ellis; Madhumita Mahalanabis; Ingrid A Beck; Gregory Pepper; Amy Wright; Shannon Hamilton; Sarah Holte; Willscott E Naugler; Diane M Pawluk; Chung-Chen Li; Lisa M Frenkel
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

5.  A strong case for viral genetic factors in HIV virulence.

Authors:  Viktor Müller; Christophe Fraser; Joshua T Herbeck
Journal:  Viruses       Date:  2011-03-08       Impact factor: 5.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.